Tülek Fırat, Kahraman Alper
Memorial Ataşehir Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey
University of Health Sciences Turkey, Haseki Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey
Turk J Obstet Gynecol. 2021 Dec 24;18(4):285-290. doi: 10.4274/tjod.galenos.2021.03439.
This study aimed to evaluate the effects of adjuvant growth hormone (GH) therapy on in vitro fertilization outcomes in women with infertility with expected normal ovarian response who underwent gonadotropin-releasing hormone (GnRH) antagonist protocol with dual triggering.
Records of women who underwent GnRH antagonist cycles with dual triggering in a single tertiary center between 2017 and 2020 were retrospectively analyzed. A total of 1054 women with expected normal ovarian response were evaluated, of which 131 were found to receive GH co-treatment (study group). Moreover, 950 women did not receive any adjuvant therapy (control group). Their cycle outcomes were compared.
The number of retrieved oocytes, oocyte maturation rates, quality of embryos, miscarriage rates, and multiple pregnancy rates were comparable among women who underwent GnRH antagonist cycles with and without GH co-treatment. The number of obtained 2PN embryos (5.68±2.46 vs 5.06±2.5; p=0.003), fertilization rates (0.84±0.16 vs 0.76±0.18; p<0.001), implantation rates (0.34 vs 0.25; p=0.006), clinical pregnancy rates (50.4% vs 38%; p=0.008), and live birth delivery rates (41.8% vs 32.2%; p=0.007) were significantly higher in women who received GH co-treatment.
GH co-treatment significantly increased the clinical pregnancy rates and live birth delivery rates in women with infertility and expected normal ovarian response who underwent GnRH antagonist protocol with dual triggering for oocyte maturation, which was possibly due to the increasing endometrial receptivity or improving oocyte quality.
本研究旨在评估辅助生长激素（GH）治疗对预期卵巢反应正常的不孕女性体外受精结局的影响，这些女性采用促性腺激素释放激素（GnRH）拮抗剂方案并进行双重触发。
回顾性分析2017年至2020年在单一三级中心接受GnRH拮抗剂方案双重触发的女性记录。共评估了1054名预期卵巢反应正常的女性，其中131名接受了GH联合治疗（研究组）。此外，950名女性未接受任何辅助治疗（对照组）。比较了她们的周期结局。
在接受和未接受GH联合治疗的GnRH拮抗剂周期女性中，回收的卵母细胞数量、卵母细胞成熟率、胚胎质量、流产率和多胎妊娠率相当。接受GH联合治疗的女性获得的2PN胚胎数量（5.68±2.46对5.06±2.5；p=0.003）、受精率（0.84±0.16对0.76±0.18；p<0.001）、着床率（0.34对0.25；p=0.006）、临床妊娠率（50.4%对38%；p=0.008）和活产率（41.8%对32.2%；p=0.007）显著更高。
对于接受GnRH拮抗剂方案双重触发进行卵母细胞成熟的预期卵巢反应正常的不孕女性，GH联合治疗显著提高了临床妊娠率和活产率，这可能是由于子宫内膜容受性增加或卵母细胞质量改善。
